company background image
PEN logo

Penumbra NYSE:PEN Stock Report

Last Price

US$222.15

Market Cap

US$8.6b

7D

-8.1%

1Y

-16.5%

Updated

18 Mar, 2024

Data

Company Financials +

PEN Stock Overview

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally.

PEN fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance3/6
Financial Health6/6
Dividends0/6

Rewards

Risk Analysis

No risks detected for PEN from our risk checks.

Penumbra, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Penumbra
Historical stock prices
Current Share PriceUS$222.15
52 Week HighUS$348.67
52 Week LowUS$180.93
Beta0.52
1 Month Change-17.89%
3 Month Change-11.87%
1 Year Change-16.54%
3 Year Change-16.92%
5 Year Change41.27%
Change since IPO437.89%

Recent News & Updates

Recent updates

Some Investors May Be Worried About Penumbra's (NYSE:PEN) Returns On Capital

Jan 23
Some Investors May Be Worried About Penumbra's (NYSE:PEN) Returns On Capital

A Look At The Fair Value Of Penumbra, Inc. (NYSE:PEN)

Nov 16
A Look At The Fair Value Of Penumbra, Inc. (NYSE:PEN)

Penumbra: Appeal Improves, Just Not Appealing Yet

Oct 16

Returns On Capital Signal Tricky Times Ahead For Penumbra (NYSE:PEN)

Oct 05
Returns On Capital Signal Tricky Times Ahead For Penumbra (NYSE:PEN)

Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy

Sep 01

A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)

Aug 15
A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)

Penumbra (NYSE:PEN) Has Some Way To Go To Become A Multi-Bagger

Jun 28
Penumbra (NYSE:PEN) Has Some Way To Go To Become A Multi-Bagger

Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors

Jun 22

Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult

Jun 02
Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult

We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn

Apr 01
We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn

Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M

Feb 23

Penumbra Riding Higher On Upcoming Launches And Rerating

Jan 12

Penumbra: Today's Best Medical Equipment Nearby Cap-Gain Buy

Nov 03

Penumbra cut to Neutral at Citi on macro concerns

Oct 05

Penumbra, Asahi team up to bring blood clot removing device Indigo to Japan

Sep 22

Penumbra stock rises ~11% after announcing European launch of catheters for stroke care

Sep 07

Sector Rerating Has Cast A Shadow Over Penumbra

Aug 18

Penumbra gains as RBC initiates at Outperform with 59% upside

Jul 18

Penumbra: Multiple Downside Targets, Rescued By Long-Term Value Proposition

Jun 10

Penumbra A Little Beaten Down Despite Strong Growth Opportunities

Mar 01

Returns On Capital Are Showing Encouraging Signs At Penumbra (NYSE:PEN)

Dec 01
Returns On Capital Are Showing Encouraging Signs At Penumbra (NYSE:PEN)

Shareholder Returns

PENUS Medical EquipmentUS Market
7D-8.1%-1.5%-0.1%
1Y-16.5%12.2%28.4%

Return vs Industry: PEN underperformed the US Medical Equipment industry which returned 12.2% over the past year.

Return vs Market: PEN underperformed the US Market which returned 28.4% over the past year.

Price Volatility

Is PEN's price volatile compared to industry and market?
PEN volatility
PEN Average Weekly Movement5.7%
Medical Equipment Industry Average Movement8.0%
Market Average Movement6.1%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.0%

Stable Share Price: PEN has not had significant price volatility in the past 3 months.

Volatility Over Time: PEN's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
20044,200Adam Elsesserhttps://www.penumbrainc.com

Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX Select, BENCHMARK, BMX96, BMX81, DDC, SENDit, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization Device, aspiration tubing, and aspiration pump under the Penumbra RED, JET, ACE, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that includes the Penumbra Coil 400, a detachable coil that provides an alternative for the treatment of aneurysms and other complex lesions, as well as Penumbra SMART COIL, a detachable coil to treat patients with a wide range of neurovascular lesions; and POD400 and PAC400 brands.

Penumbra, Inc. Fundamentals Summary

How do Penumbra's earnings and revenue compare to its market cap?
PEN fundamental statistics
Market capUS$8.60b
Earnings (TTM)US$90.95m
Revenue (TTM)US$1.06b

94.5x

P/E Ratio

8.1x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PEN income statement (TTM)
RevenueUS$1.06b
Cost of RevenueUS$375.88m
Gross ProfitUS$682.64m
Other ExpensesUS$591.69m
EarningsUS$90.95m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)2.35
Gross Margin64.49%
Net Profit Margin8.59%
Debt/Equity Ratio0%

How did PEN perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.